The FDA released an action plan to address the Accelerating Access to Critical Therapies for ALS (amyotrophic lateral sclerosis) Act.
The FDA on Thursday released its action plan for developing therapies to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), following through on its duties under a law signed late last year.
The agency released the action plan in a statement.
The Accelerating Access to Critical Therapies for ALS Act (ACT for ALS), which was signed into law by President Joe Biden, requires the HHS to implement a public-private partnership for Rare Neurodegenerative Diseases through cooperative agreements or contracts. These agreements, established through the FDA and the National Institutes of Health (NIH), would help foster development of treatments for ALS and other rare neurodegenerative diseases.
The act required FDA to publish and implement a 5-year action plan in order to foster drug development and facilitate access to investigational drugs for ALS and other rare neurogenerative diseases. It also requires the FDA to award grants or contracts to public and private entities that would cover costs of research on and development of interventions that are designed to prevent, diagnose, mitigate, treat, or cure ALS and rare neurodegenerative diseases in adults and children.
Also included in the action plan were elements to facilitate
The ACT for ALS allocates $100 million for each of the fiscal years 2022 to 2026 to carry out these goals. The action plan is contingent on the FDA receiving these funds each year. The action plan is open for public comment from stakeholders.
“We recognize the urgent need for new treatments that can both improve and extend the lives of people diagnosed with [rare neurodegenerative diseases],” FDA Commissioner Robert M Califf, MD said in a statement. “This action plan, especially including the use of public-private partnerships and direct involvement of patients, will ensure the FDA is working toward meeting the task set forth by Congress to enhance the quality of life for those suffering by facilitating access to new therapies.
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More